Two drugmakers are joining forces to let artificial intelligence help design a new cancer treatment.
According to a release surfaced via Bing News and published on VentureBeat, LabGenius Therapeutics and LG Chem have entered a multi-year research collaboration, option and license agreement. The goal is to develop a tumour-targeting antibody designed using AI and machine learning.
Under the deal, the announcement says LabGenius Therapeutics will apply its AI/ML platform to the discovery and design work. The arrangement also includes an option and licensing component, which typically gives a partner the right to license a resulting drug candidate as the work progresses. The specific terms beyond that structure were not detailed in the source.
A bit of context on the players, drawn only from the announcement: LabGenius is a therapeutics company that uses AI and machine learning to design antibodies, while LG Chem is the partner entering the collaboration. The target of the program is a tumour-targeting antibody — a type of drug engineered to home in on cancer cells.
The available source is a single news summary, so financial figures, timelines and the specific cancer being targeted were not provided.
Why it matters: antibody drugs are among the most important and expensive tools in modern cancer care, and designing them has traditionally been slow, costly and trial-heavy. Deals like this one are a signal that pharmaceutical companies increasingly see AI-driven design not as an experiment but as a practical route to discovering the next generation of targeted medicines.